Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s Breakthrough Designations Face Question Of Review Resources

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Woodcock says FDA will manage breakthrough applications along with its entire portfolio of submissions, but some stakeholders express concern about whether the demands of the exceedingly popular program will affect the agency’s handling of other applications.

You may also be interested in...



Could US FDA User Fee Bill Include The Long-Sought 505(b)(2) Pathway For Biosimilars?

Former FDA official says the pathway is needed to avoid wasted sponsor time and effort.

Could US FDA User Fee Bill Include The Long-Sought 505(b)(2) Pathway For Biosimilars?

Former FDA official says the pathway is needed to avoid wasted sponsor time and effort.

PhRMA, BIO’s PDUFA V Application Tracker Could Inform “Course Corrections”

Members will enter data into secure database, allowing trade groups to gauge trends and problems with the PDUFA V application review program – and giving industry a stronger negotiating position for the next user fee round.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS005532

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel